Danaher (NYSE:DHR – Get Free Report) was upgraded by analysts at Royal Bank Of Canada to a “moderate buy” rating in a research note issued to investors on Thursday,Zacks.com reports.
A number of other research analysts have also weighed in on DHR. Robert W. Baird decreased their target price on Danaher from $251.00 to $249.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Wolfe Research decreased their target price on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Morgan Stanley decreased their price objective on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Finally, JPMorgan Chase & Co. decreased their price objective on Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a report on Wednesday, April 22nd. Nineteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.65.
Get Our Latest Report on Danaher
Danaher Stock Down 1.6%
Danaher (NYSE:DHR – Get Free Report) last posted its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm’s revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.88 EPS. As a group, research analysts anticipate that Danaher will post 8.43 EPS for the current year.
Insider Buying and Selling
In other Danaher news, EVP Gregory M. Milosevich sold 1,320 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This represents a 20.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 10.80% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Danaher during the 4th quarter valued at $2,177,106,000. Viking Global Investors LP lifted its position in shares of Danaher by 543.9% during the 2nd quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after acquiring an additional 2,455,994 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Danaher by 104.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock valued at $991,923,000 after acquiring an additional 2,216,789 shares during the period. Generation Investment Management LLP lifted its position in shares of Danaher by 34.0% during the 3rd quarter. Generation Investment Management LLP now owns 6,654,666 shares of the conglomerate’s stock valued at $1,319,354,000 after acquiring an additional 1,689,020 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after acquiring an additional 1,517,904 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.
About Danaher
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Further Reading
- Five stocks we like better than Danaher
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
